title: BRAF Inhibitor-Induced Panniculitis: Appearance on 18F-FDG PET/CT.
abstract: BRAF inhibitors vemurafenib and dabrafenib have become the standard of care for treatment of stage IV metastatic melanoma harboring a BRAF mutation. Panniculitis is a rare but known adverse side effect of these agents and presents with tender erythematous nodules. These nodules may demonstrate uptake on F-FDG PET/CT, which may mimic metastatic disease in patients undergoing treatment. We present a case of BRAF inhibitor-induced panniculitis in a patient with stage IV metastatic melanoma and discuss the imaging findings on F-FDG PET/CT.
authors.affiliation: From the Department of Radiology, Mayo Clinic, Rochester, MN.
authors.forename: Stephen M
authors.initials: SM
authors.lastname: Broski
authors.forename: Erin K
authors.initials: EK
authors.lastname: Moran
authors.forename: Katrina N
authors.initials: KN
authors.lastname: Glazebrook
authors.forename: Mark A
authors.initials: MA
authors.lastname: Nathan
mesh_terms: D000328:Adult; D019788:Fluorodeoxyglucose F18; D006801:Humans; D007093:Imidazoles / Q000009:adverse effects; D007211:Indoles / Q000009:adverse effects; D008297:Male; D008545:Melanoma / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology; D064847:Multimodal Imaging; D009362:Neoplasm Metastasis; D010091:Oximes / Q000009:adverse effects; D015434:Panniculitis / Q000000981:diagnostic imaging* / Q000209:etiology; D049268:Positron-Emission Tomography; D048493:Proto-Oncogene Proteins B-raf / Q000037:antagonists & inhibitors*; D019275:Radiopharmaceuticals; D013449:Sulfonamides / Q000009:adverse effects; D014057:Tomography, X-Ray Computed; D000077484:Vemurafenib
chemical_list: D007093:Imidazoles; D007211:Indoles; D010091:Oximes; D019275:Radiopharmaceuticals; D013449:Sulfonamides; D019788:Fluorodeoxyglucose F18; D000077484:Vemurafenib; D048493:Proto-Oncogene Proteins B-raf; C561627:dabrafenib